ERBB2 and urinary bladder carcinoma: Interestingly, this study also found that cisplatin-resistant bladder cancer cells exhibit higher HER2 expression and higher T-DM1 sensitivity, and overexpression of HER2 may contribute to development of metastatic tumors (Hayashi et al., 2015).